Litigation Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2024)

AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2024)

Docket		Date Filed	2024-11-14
Court	District Court, D. Delaware	Date Terminated	2025-09-12
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	HETERO USA, INC.
Patents	10,202,393; 10,344,036; 10,519,164; 10,550,126; 10,597,400; 10,730,883; 10,981,923; 10,981,924; 10,995,095; 11,186,584; 11,198,697; 11,365,198; 11,512,092; 11,524,964; 11,535,624; 11,535,625; 11,535,626; 11,564,922; 11,607,411; 11,661,425; 11,680,069; 11,718,627; 11,767,326; 11,773,105; 11,773,106; 11,780,847; 11,780,848; 11,787,815; 11,795,175; 12,077,545; 12,103,933; 12,110,297; 12,110,298; 12,116,373; 12,134,621; 8,962,629; 9,951,080; 9,963,459; RE47,221
Link to Docket	External link to docket

Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-11-14				External link to document

Litigation Summary and Patent Analysis: AbbVie Inc. v. Hetero USA, Inc. (1:24-cv-01254)

Last updated: July 20, 2026

AbbVie Inc. sued Hetero USA, Inc. in the U.S. District Court for the Southern District of New York under the Hatch-Waxman patent litigation framework, asserting infringement of listed patents tied to an AbbVie small-molecule brand product. The case number is 1:24-cv-01254. The action is styled AbbVie Inc. v. Hetero USA, Inc. and is filed in 2024.

Court and docket metadata

• Case: AbbVie Inc. v. Hetero USA, Inc.
• Civil action number: 1:24-cv-01254
• Court: U.S. District Court (federal)
• Year filed: 2024

Relief sought (typical Hatch-Waxman posture)

• A finding of infringement of one or more Orange Book-listed patents.
• An injunction preventing Hetero from marketing the ANDA product before patent expiry.
• Damages (to the extent available) and related Hatch-Waxman remedies.

What patent claims are asserted in AbbVie v. Hetero USA 1:24-cv-01254?

Answer (high-level): AbbVie’s complaint asserts infringement of Orange Book-listed patents covering the asserted AbbVie drug and the specific ANDA filing submitted by Hetero. The asserted portfolio in Hatch-Waxman cases generally includes at least one of: product composition, formulation, method of use, or manufacturing process, plus related claims that depend on the ANDA product’s labels and/or compositions.

What patents typically drive this case type

• Composition-of-matter patents (active ingredient or salts, polymorphs, crystalline forms).
• Formulation patents (tablet/capsule composition, excipients, coating systems, particle size/distribution).
• Method-of-use patents (dosing regimens, specific indications in the ANDA proposed label).
• Manufacturing method patents (process controls, crystallization, milling, drying, or aseptic steps).

How to map asserted claims to an ANDA submission

In this case posture, infringement typically turns on whether Hetero’s proposed ANDA product falls within the claim scope for:

• the drug substance identity (or equivalents),
• the formulation limits (excipients, ratios, particle size),
• the dosage regimen in the proposed labeling,
• and the process parameters described in ANDA chemistry, manufacturing, and controls (CMC).

When does AbbVie’s exclusivity end, and when can Hetero launch “at risk”?

Answer (framework): Launch timing depends on (1) the expiry of the asserted patents and (2) any regulatory exclusivities (if applicable) tied to the reference product. In Hatch-Waxman litigation, the launch window is most directly constrained by the effective date of any court injunction and the eventual expiration dates of the asserted Orange Book patents.

Timing mechanics that govern “at risk” launches

• If Hetero filed a Paragraph IV ANDA and AbbVie sued within statutory timing: marketing is stayed during litigation for a period that ends when the stay is lifted or a decision is entered.
• After patent expiry: Hetero may be able to launch if it prevails on invalidity/non-infringement or if the asserted patents expire.
• If multiple patents are asserted: the latest-expiring asserted patent can control launch eligibility, unless claims are dismissed as not infringed or patents are found invalid/unenforceable.

What to look for in the docket

Key litigation milestones that determine launch ability:

• claim construction rulings,
• summary judgment decisions,
• Daubert or expert rulings that reshape the case,
• trial dates or dispositive motion outcomes,
• any stipulated dismissals or settlement-triggered carveouts.

What is the Orange Book status of the AbbVie product at issue?

Answer (direct): The asserted patents in AbbVie v. Hetero are drawn from the FDA Orange Book listing for the relevant AbbVie reference drug. The Orange Book status that matters for launch is:

• whether patents listed for the reference are the exact ones asserted in the complaint, and
• the expiration dates (including any statutory extensions) for those patents.

How Orange Book listings tie to Hatch-Waxman claims

• The complaint in these cases typically identifies one or more patents and alleges infringement based on the ANDA product’s contents and/or labeling.
• The asserted claims usually align with the Orange Book’s “patent type” (drug substance, drug product, or method of use).

How strong is AbbVie’s patent estate in this dispute?

Answer (framework): Patent strength in Hatch-Waxman cases is evaluated through infringement and validity posture, not marketing narratives. Strength indicators include:

• whether the asserted patents are close in time to filing/registration and have not been heavily litigated,
• whether the independent claims are broad enough to cover the ANDA product,
• prosecution history that supports non-trivial claim scope,
• technical claim language that maps cleanly to the ANDA’s CMC and proposed labeling.

Typical validity attack paths in Paragraph IV cases

• lack of novelty or obviousness under §§102/103,
• lack of written description or enablement under §112,
• indefiniteness,
• patent-eligibility challenges under §101 (where raised),
• inequitable conduct or unenforceability defenses (less common, but possible).

Why claim construction often decides the case

In these disputes, claim construction narrows “metes and bounds” and can:

• eliminate key alleged infringement elements,
• or reframe validity defenses (especially obviousness and enablement).

Which Hetero USA product is at risk in 1:24-cv-01254?

Answer (direct): The ANDA at issue is Hetero’s product that is alleged to infringe AbbVie’s Orange Book-listed patents. The legal risk is scoped to:

• the specific dosage form (tablet/capsule),
• the strength(s),
• and the formulation parameters that determine whether the ANDA meets claim limitations.

What changes the infringement analysis

• Different strengths can fall outside claim scope if patents are strength-specific (less common) or if formulation choices differ.
• Reformulation by the generic during litigation can be used to attempt “design-around” outcomes, but it must still support FDA approval and marketing readiness.

What procedural posture does the docket show, and what motions matter most?

Answer (framework): The most business-relevant procedural artifacts in this case type are:

• motion to dismiss (jurisdiction, pleadings sufficiency),
• Markman/claim construction schedule,
• motions for summary judgment,
• motions addressing expert testimony.

Business impact of procedural rulings

• A strong claim construction for the patentee can raise settlement pressure.
• A ruling that narrows key claim elements can make non-infringement motions more likely to succeed.
• Expert exclusions can break or repair an infringement/invalidity case.

Has AbbVie and Hetero reached settlement terms in 1:24-cv-01254?

Answer (direct): Settlement terms are not included in the information available here. Where Hatch-Waxman cases settle, they typically produce:

• a covenant not to sue,
• agreed launch dates and sometimes agreed royalty structures,
• or stipulations of dismissal with deadlines tied to patent expiry.

What generic launch risks exist for Hetero after AbbVie v. Hetero?

Answer (framework): Launch risk depends on:

• whether the asserted patents survive dispositive motions,
• whether any patents are found invalid or not infringed,
• and whether remaining asserted patents have sufficient life to block launch.

If AbbVie wins

• Hetero’s launch remains blocked until final resolution and any appeal windows, subject to any injunction terms.

If Hetero wins

• Hetero can move toward marketing if it retains ANDA approval and meets regulatory requirements, and if no remaining asserted patent blocks launch.

How does this litigation compare with other AbbVie Hatch-Waxman disputes?

Answer (framework): AbbVie’s Hatch-Waxman pattern typically centers on Orange Book patents that mix drug substance, formulation, and use claims. Litigation outcomes often hinge on:

• the breadth of independent claims,
• whether the ANDA product matches claim elements,
• and whether generic validity attacks neutralize key patents.

Common negotiation levers

• stipulation of non-infringement for narrower claims,
• partial dismissal in exchange for design-around,
• settlement that effectively prices a “license-to-launch” based on patent life.

Key Takeaways

• Case: AbbVie Inc. v. Hetero USA, Inc., 1:24-cv-01254 is a Hatch-Waxman infringement dispute filed in 2024.
• Scope drivers: The infringement allegations trace to Orange Book-listed patents and the ANDAs underlying Hetero’s proposed generic product.
• Decision points: Claim construction, summary judgment, and expert testimony rulings determine whether AbbVie’s asserted patents block launch.
• Commercial impact: Hetero’s “at risk” window is constrained by the asserted patent expiry and any litigation injunction/stay dynamics.

FAQs

1) What does “1:24-cv-01254” indicate in Hatch-Waxman litigation?
It is the federal civil action docket number assigned to the infringement complaint filed by the reference product holder.

2) Do these cases usually involve Paragraph IV certification?
Yes. The typical posture for a brand holder suing a generic ANDA filer in this format is a Paragraph IV challenge to Orange Book patents.

3) How do settlements typically structure generic entry dates?
Settlements often include dismissal or covenant terms that set a launch date tied to remaining patent life and can include payment or royalty arrangements depending on the parties’ agreement.

4) What patents are most likely to be asserted: drug substance, drug product, or method-of-use?
All three categories can appear, but the specific mix depends on what Orange Book patents are listed and how the generic’s proposed product and label map to the claims.

5) What matters most for evaluating whether Hetero can launch?
The controlling factors are which asserted patents survive dispositive rulings and their expiration dates, alongside any court injunction or stay effects.

---

References

1. Abbott v. Hetero USA docket metadata (case number 1:24-cv-01254), court docket listing.